Legal & General Group’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.9M | Buy |
77,569
+3,214
| +4% | +$119K | ﹤0.01% | 1815 |
|
|
2026
Q1 | $2.7M | Sell |
74,355
-13,447
| -15% | -$601K | ﹤0.01% | 1787 |
|
|
2025
Q4 | $4.09M | Sell |
87,802
-6,007
| -6% | -$267K | ﹤0.01% | 1671 |
|
|
2025
Q3 | $3.91M | Sell |
93,809
-3,723
| -4% | -$119K | ﹤0.01% | 1697 |
|
|
2025
Q2 | $2.81M | Buy |
97,532
+8,905
| +10% | +$275K | ﹤0.01% | 1827 |
|
|
2025
Q1 | $2.97M | Sell |
88,627
-312
| -0.4% | -$11.7K | ﹤0.01% | 1770 |
|
|
2024
Q4 | $4.55M | Buy |
88,939
+18,443
| +26% | +$1.03M | ﹤0.01% | 1620 |
|
|
2024
Q3 | $3.6M | Buy |
70,496
+1,738
| +3% | +$89.6K | ﹤0.01% | 1724 |
|
|
2024
Q2 | $3.08M | Buy |
68,758
+4,806
| +8% | +$222K | ﹤0.01% | 1759 |
|
|
2024
Q1 | $2.99M | Buy |
63,952
+9,847
| +18% | +$385K | ﹤0.01% | 1757 |
|
|
2023
Q4 | $1.93M | Buy |
54,105
+502
| +0.9% | +$15.4K | ﹤0.01% | 1974 |
|
|
2023
Q3 | $1.59M | Buy |
53,603
+15,755
| +42% | +$325K | ﹤0.01% | 1997 |
|
|
2023
Q2 | $682K | Buy |
37,848
+15,301
| +68% | +$305K | ﹤0.01% | 2352 |
|
|
2023
Q1 | $362K | Buy |
22,547
+6,601
| +41% | +$122K | ﹤0.01% | 2405 |
|
|
2022
Q4 | $292K | Buy |
15,946
+685
| +4% | +$12.1K | ﹤0.01% | 2475 |
|
|
2022
Q3 | $300K | Buy |
15,261
+831
| +6% | +$16.9K | ﹤0.01% | 2476 |
|
|
2022
Q2 | $269K | Buy |
14,430
+189
| +1% | +$3.77K | ﹤0.01% | 2531 |
|
|
2022
Q1 | $313K | Buy |
14,241
+390
| +3% | +$7.89K | ﹤0.01% | 2524 |
|
|
2021
Q4 | $393K | Buy |
13,851
+4,275
| +45% | +$105K | ﹤0.01% | 2489 |
|
|
2021
Q3 | $202K | Buy |
9,576
+4,483
| +88% | +$93.8K | ﹤0.01% | 2689 |
|
|
2021
Q2 | $96K | Buy |
5,093
+858
| +20% | +$15.1K | ﹤0.01% | 2751 |
|
|
2021
Q1 | $64K | Buy |
4,235
+230
| +6% | +$3.56K | ﹤0.01% | 2745 |
|
|
2020
Q4 | $57K | Hold |
4,005
| – | – | ﹤0.01% | 2765 |
|
|
2020
Q3 | $63K | Sell |
4,005
-1,124
| -22% | -$17.2K | ﹤0.01% | 2612 |
|
|
2020
Q2 | $90K | Buy |
5,129
+3,257
| +174% | +$55.5K | ﹤0.01% | 2559 |
|
|
2020
Q1 | $28K | Sell |
1,872
-390
| -17% | -$7.99K | ﹤0.01% | 2784 |
|
|
2019
Q4 | $54K | Buy |
2,262
+419
| +23% | +$7.98K | ﹤0.01% | 2784 |
|
|
2019
Q3 | $28K | Hold |
1,843
| – | – | ﹤0.01% | 2992 |
|
|
2019
Q2 | $46K | Buy |
1,843
+380
| +26% | +$9.41K | ﹤0.01% | 2808 |
|
|
2019
Q1 | $33K | Buy |
1,463
+410
| +39% | +$10.1K | ﹤0.01% | 2884 |
|
|
2018
Q4 | $31K | Hold |
1,053
| – | – | ﹤0.01% | 2886 |
|
|
2018
Q3 | $30K | Buy |
+1,053
| New | +$31.3K | ﹤0.01% | 3023 |
|
Other funds holding CRNX
FCM
DCM
JT
Legal & General Group's CRNX Position: Q2 2026 in Review
Legal & General Group increased its Crinetics Pharmaceuticals (CRNX) stake by 4.3% in Q2 2026, buying an estimated $119K and bringing the position to 77,569 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1815.
Legal & General Group first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $4.55M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Legal & General Group held 77,569 shares of Crinetics Pharmaceuticals worth $2.9M as of Q2 2026.
- Legal & General Group bought 3,214 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $119K.
- Crinetics Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1815 holding.
- Legal & General Group first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Legal & General Group's Crinetics Pharmaceuticals position peaked at $4.55M in Q4 2024.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.